Current and Emerging Strategies for Tubo-Ovarian Cancer Diagnostics

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2023 Nov 14

PMID 37958227

Authors

Mark R Brincat

Ana Rita Mira

Alexandra Lawrence

Affiliations

Soon will be listed here.

Abstract

Tubo-ovarian cancer is the most lethal gynaecological cancer. More than 75% of patients are diagnosed at an advanced stage, which is associated with poorer overall survival. Symptoms at presentation are vague and non-specific, contributing to late diagnosis. Multimodal risk models have improved the diagnostic accuracy of adnexal mass assessment based on patient risk factors, coupled with findings on imaging and serum-based biomarker tests. Newly developed ultrasonographic assessment algorithms have standardised documentation and enable stratification of care between local hospitals and cancer centres. So far, no screening test has proven to reduce ovarian cancer mortality in the general population. This review is an update on the evidence behind ovarian cancer diagnostic strategies.

Citing Articles

Integrative Analysis of Gene Expression and Promoter Methylation to Differentiate High-Grade Serous Ovarian Cancer from Benign Tumors.

Vaicekauskaite I, Kazlauskaite P, Gineikaite R, ciurliene R, Lazutka J, Sabaliauskaite R Biomedicines. 2025; 13(2).

PMID: 40002854 PMC: 11853219. DOI: 10.3390/biomedicines13020441.

References

Seidman J, Kurman R, Ronnett B . Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003; 27(7):985-93. DOI: 10.1097/00000478-200307000-00014. View

Moore R, Miller M, DiSilvestro P, Landrum L, Gajewski W, Ball J . Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011; 118(2 Pt 1):280-288. PMC: 3594110. DOI: 10.1097/AOG.0b013e318224fce2. View

Aramendia-Vidaurreta V, Cabeza R, Villanueva A, Navallas J, Alcazar J . Ultrasound Image Discrimination between Benign and Malignant Adnexal Masses Based on a Neural Network Approach. Ultrasound Med Biol. 2015; 42(3):742-52. DOI: 10.1016/j.ultrasmedbio.2015.11.014. View

Bankhead C, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A . Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG. 2008; 115(8):1008-14. PMC: 2607526. DOI: 10.1111/j.1471-0528.2008.01772.x. View

Zhang H, Mao Y, Chen X, Wu G, Liu X, Zhang P . Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. Eur Radiol. 2019; 29(7):3358-3371. DOI: 10.1007/s00330-019-06124-9. View

Li B, Pu K, Ge L, Wu X . Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis. Gene. 2019; 714:143993. DOI: 10.1016/j.gene.2019.143993. View

Kawakami E, Tabata J, Yanaihara N, Ishikawa T, Koseki K, Iida Y . Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers. Clin Cancer Res. 2019; 25(10):3006-3015. DOI: 10.1158/1078-0432.CCR-18-3378. View

Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S . Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2020; 158(2):316-322. PMC: 7453382. DOI: 10.1016/j.ygyno.2020.05.002. View

Rosenbaum S, Lind T, Antoch G, Bockisch A . False-positive FDG PET uptake--the role of PET/CT. Eur Radiol. 2005; 16(5):1054-65. DOI: 10.1007/s00330-005-0088-y. View

10.

Timmerman D, Van Calster B, Testa A, Guerriero S, Fischerova D, Lissoni A . Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound Obstet Gynecol. 2010; 36(2):226-34. DOI: 10.1002/uog.7636. View

11.

Alcazar J, Caparros M, Arraiza M, Minguez J, Guerriero S, Chiva L . Pre-operative assessment of intra-abdominal disease spread in epithelial ovarian cancer: a comparative study between ultrasound and computed tomography. Int J Gynecol Cancer. 2019; 29(2):227-233. DOI: 10.1136/ijgc-2018-000066. View

12.

Lycke M, Kristjansdottir B, Sundfeldt K . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018; 151(1):159-165. DOI: 10.1016/j.ygyno.2018.08.025. View

13.

C Grossman D, Curry S, Owens D, Barry M, Davidson K, Doubeni C . Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319(6):588-594. DOI: 10.1001/jama.2017.21926. View

14.

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

15.

Tanizaki Y, Kobayashi A, Shiro M, Ota N, Takano R, Mabuchi Y . Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer. Int J Gynecol Cancer. 2014; 24(3):454-60. DOI: 10.1097/IGC.0000000000000074. View

16.

Carver T, Hartley S, Lee A, Cunningham A, Archer S, de Villiers C . CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. Cancer Epidemiol Biomarkers Prev. 2020; 30(3):469-473. PMC: 7611188. DOI: 10.1158/1055-9965.EPI-20-1319. View

17.

Carreras-Dieguez N, Glickman A, Munmany M, Casanovas G, Agusti N, Diaz-Feijoo B . Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors. Diagnostics (Basel). 2022; 12(1). PMC: 8774736. DOI: 10.3390/diagnostics12010226. View

18.

Testa A, Kaijser J, Wynants L, Fischerova D, Van Holsbeke C, Franchi D . Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. Br J Cancer. 2014; 111(4):680-8. PMC: 4134495. DOI: 10.1038/bjc.2014.333. View

19.

Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M . The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in and . J Med Genet. 2022; 60(5):440-449. PMC: 10176325. DOI: 10.1136/jmg-2022-108741. View

20.

Van Calster B, Van Hoorde K, Valentin L, Testa A, Fischerova D, Van Holsbeke C . Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ. 2014; 349:g5920. PMC: 4198550. DOI: 10.1136/bmj.g5920. View